117 related articles for article (PubMed ID: 36382626)
1. Identification of prognostic factors in classic Hodgkin lymphoma by integrating whole slide imaging and next generation sequencing.
Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Catalina-Fernandez I; Fernandez-Valle MDC; Romero-Garcia R; Garcia-Rojo M
Mol Omics; 2022 Dec; 18(10):1015-1028. PubMed ID: 36382626
[TBL] [Abstract][Full Text] [Related]
2. Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.
Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Maira-Gonzalez N; Garcia-Rojo M
Front Oncol; 2022; 12():1000762. PubMed ID: 36338756
[TBL] [Abstract][Full Text] [Related]
3. Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP.
Jachimowicz RD; Pieper L; Reinke S; Gontarewicz A; Plütschow A; Haverkamp H; Frauenfeld L; Fend F; Overkamp M; Jochims F; Thorns C; Leo Hansmann M; Möller P; Rosenwald A; Stein H; Reinhardt HC; Borchmann P; von Tresckow B; Engert A; Klapper W
Haematologica; 2021 Jun; 106(6):1684-1692. PubMed ID: 32381573
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of the Expression of Latent-Membrane Protein 1 of Epstein-Barr Virus in Classical Hodgkin Lymphoma.
Santisteban-Espejo A; Perez-Requena J; Atienza-Cuevas L; Moran-Sanchez J; Fernandez-Valle MDC; Bernal-Florindo I; Romero-Garcia R; Garcia-Rojo M
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960792
[TBL] [Abstract][Full Text] [Related]
5. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.
van Bladel DAG; Stevens WBC; Kroeze LI; de Groen RAL; de Groot FA; van der Last-Kempkes JLM; Berendsen MR; Rijntjes J; Luijks JACW; Bonzheim I; van der Spek E; Plattel WJ; Pruijt JFM; de Jonge-Peeters SDPWM; Velders GA; Lensen C; van Bladel ER; Federmann B; Hoevenaars BM; Pastorczak A; van der Werff Ten Bosch J; Vermaat JSP; Nooijen PTGA; Hebeda KM; Fend F; Diepstra A; van Krieken JHJM; Groenen PJTA; van den Brand M; Scheijen B
Blood Adv; 2023 Oct; 7(19):5911-5924. PubMed ID: 37552109
[TBL] [Abstract][Full Text] [Related]
6. Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.
Juskevicius D; Jucker D; Dietsche T; Perrina V; Rufle A; Ruiz C; Dirnhofer S; Tzankov A
Lab Invest; 2018 Nov; 98(11):1487-1499. PubMed ID: 30087457
[TBL] [Abstract][Full Text] [Related]
7. Pathway-focused gene expression profiles and immunohistochemistry detection identify contrasting association of caspase 3 (CASP3) expression with prognosis in pediatric classical Hodgkin lymphoma.
Vera-Lozada G; Segges P; Stefanoff CG; Barros MHM; Niedobitek G; Hassan R
Hematol Oncol; 2018 Oct; 36(4):663-670. PubMed ID: 29901224
[TBL] [Abstract][Full Text] [Related]
8. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
10. Validation of the Oncomine
Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
[TBL] [Abstract][Full Text] [Related]
11. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
[TBL] [Abstract][Full Text] [Related]
12. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.
Eberle FC; Song JY; Xi L; Raffeld M; Harris NL; Wilson WH; Pittaluga S; Jaffe ES
Am J Surg Pathol; 2012 May; 36(5):716-25. PubMed ID: 22367293
[TBL] [Abstract][Full Text] [Related]
13. Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.
Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Spina V; Bruscaggin A; Cuccaro A; Martini M; Di Trani M; Forestieri G; Manzoni M; Condoluci A; Arribas A; Terzi-Di-Bergamo L; Locatelli SL; Cupelli E; Ceriani L; Moccia AA; Stathis A; Nassi L; Deambrogi C; Diop F; Guidetti F; Cocomazzi A; Annunziata S; Rufini V; Giordano A; Neri A; Boldorini R; Gerber B; Bertoni F; Ghielmini M; Stüssi G; Santoro A; Cavalli F; Zucca E; Larocca LM; Gaidano G; Hohaus S; Carlo-Stella C; Rossi D
Blood; 2018 May; 131(22):2413-2425. PubMed ID: 29449275
[TBL] [Abstract][Full Text] [Related]
15. Detection of immunoglobulin heavy chain gene rearrangements in classic hodgkin lymphoma using commercially available BIOMED-2 primers.
Chute DJ; Cousar JB; Mahadevan MS; Siegrist KA; Silverman LM; Stoler MH
Diagn Mol Pathol; 2008 Jun; 17(2):65-72. PubMed ID: 18382369
[TBL] [Abstract][Full Text] [Related]
16. Deep targeted sequencing of cytological tumor cells using whole genome amplification.
Amemiya K; Hirotsu Y; Mochizuki H; Higuchi R; Nakagomi T; Goto T; Oyama T; Kondo T; Omata M
Cancer Cytopathol; 2023 Jan; 131(1):58-68. PubMed ID: 36219530
[TBL] [Abstract][Full Text] [Related]
17. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
[TBL] [Abstract][Full Text] [Related]
18. Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma.
Tashkandi H; Petrova-Drus K; Batlevi CL; Arcila ME; Roshal M; Sen F; Yao J; Baik J; Bilger A; Singh J; de Frank S; Kumar A; Aryeequaye R; Zhang Y; Dogan A; Xiao W
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31395597
[TBL] [Abstract][Full Text] [Related]
19. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
20. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.
Gailey MP; Stence AA; Jensen CS; Ma D
Cancer Cytopathol; 2015 Jan; 123(1):30-9. PubMed ID: 25186473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
